{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:30:50Z","timestamp":1785447050193,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The clinical significance of medullary abnormalities in the appendicular skeleton detected by computed tomography (CT) in patients with multiple myeloma (MM) remains incompletely elucidated. This study aims to validate novel low-dose CT-based methods for quantifying myeloma bone marrow (BM) volume in the appendicular skeleton of MM patients undergoing [\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]FDG PET\/CT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Seventy-two newly diagnosed, transplantation eligible MM patients enrolled in the randomised phase 3 GMMG-HD7 trial underwent whole-body [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT prior to treatment and after induction therapy with either isatuximab plus lenalidomide, bortezomib, and dexamethasone or lenalidomide, bortezomib, and dexamethasone alone. Two CT-based methods using the Medical Imaging Toolkit (MITK 2.4.0.0, Heidelberg, Germany) were used to quantify BM infiltration in the appendicular skeleton: (1) Manual approach, based on calculation of the highest mean CT value (CTv) within bony canals. (2) Semi-automated approach, based on summation of CT values across the appendicular skeleton to compute cumulative CT values (cCTv). PET\/CT data were analyzed visually and via standardized uptake value (SUV) metrics, applying the Italian Myeloma criteria for PET Use (IMPeTUs). Additionally, an AI-based method was used to automatically derive whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from PET scans. Post-induction, all patients were evaluated for minimal residual disease (MRD) using BM multiparametric flow cytometry. Correlation analyses were performed between imaging data and clinical, histopathological, and cytogenetic parameters, as well as treatment response. Statistical significance was defined as\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the median CTv (manual) was 26.1 Hounsfield units (HU) and the median cCTv (semi-automated) was 5.5 HU. Both CT-based methods showed weak but significant correlations with disease burden indicators: CTv correlated with BM plasma cell infiltration (r = 0.29;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02) and \u03b22-microglobulin levels (r = 0.28;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02), while cCTv correlated with BM plasma cell infiltration (r = 0.25;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04). Appendicular CT values further demonstrated significant associations with PET-derived parameters. Notably, SUVmax values from the BM of long bones were strongly correlated with both CTv (r = 0.61;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and moderately with cCTv (r = 0.45;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Patients classified as having increased [\n                      <jats:sup>1<\/jats:sup>\n                      \u2078F]FDG uptake in the BM (Deauville Score \u2265 4), according to the IMPeTUs criteria, exhibited significantly higher CTv and cCTv values compared to those with Deauville Score &lt;4 (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002 for both). AI-based analysis of PET data revealed additional weak-to-moderate significant associations, with MTV correlating with CTv (r = 0.32;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008) and cCTv (r = 0.45;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and TLG showing correlations with CTv (r = 0.36;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002) and cCTv (r = 0.46;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Following induction therapy, CT values decreased significantly from baseline (median CTv = -13.8 HU, median cCTv = 5.2 HU;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001 for both), and CTv significantly correlated with SUVmax values from the BM of long bones (r = 0.59;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). In parallel, the incidence of follow-up pathological PET\/CT scans, SUV values, Deauville Scores, and AI-derived MTV and TLG values showed a significant reduction after therapy (all\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). No significant differences in CTv, cCTv, or PET-derived metrics were observed between MRD-positive and MRD-negative patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Novel CT-based quantification approaches for assessing BM involvement in the appendicular skeleton correlate with key clinical and PET parameters in MM. As low-dose, standardized techniques, they show promise for inclusion in MM imaging protocols, potentially enhancing assessment of disease extent and treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07599-z","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:10:40Z","timestamp":1759302640000},"page":"1509-1520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET\/CT sub-study of the Phase 3 GMMG-HD7 Trial"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Hajiyianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Piller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias K","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"Enqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Edenbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brobeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Jende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Delorme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"7599_CR1","doi-asserted-by":"crossref","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, Garc\u00eda-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20(6):e302-e312. Erratum in: Lancet Oncol. 2019;20(7):e346.","DOI":"10.1016\/S1470-2045(19)30309-2"},{"key":"7599_CR2","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1200\/EDBK_159074","volume":"35","author":"E Terpos","year":"2016","unstructured":"Terpos E, Dimopoulos MA, Moulopoulos LA. The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book. 2016;35:e407-17. https:\/\/doi.org\/10.1200\/EDBK_159074.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"4","key":"7599_CR3","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206\u201317.","journal-title":"Lancet Oncol"},{"issue":"7","key":"7599_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","volume":"133","author":"E Zamagni","year":"2019","unstructured":"Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood. 2019;133(7):644\u201351.","journal-title":"Blood."},{"issue":"12","key":"7599_CR5","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48.","journal-title":"Lancet Oncol."},{"issue":"4","key":"7599_CR6","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206\u201317.","journal-title":"Lancet Oncol"},{"issue":"10","key":"7599_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","volume":"8","author":"LA Moulopoulos","year":"2018","unstructured":"Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018;8(10):95.","journal-title":"Blood Cancer J."},{"issue":"3","key":"7599_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/j.semnuclmed.2007.01.002","volume":"37","author":"JS Blebea","year":"2007","unstructured":"Blebea JS, Houseni M, Torigian DA, Fan C, Mavi A, Zhuge Y, et al. Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med. 2007;37(3):185\u201394.","journal-title":"Semin Nucl Med"},{"issue":"3","key":"7599_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2214\/AJR.20.23204","volume":"216","author":"V Koutoulidis","year":"2021","unstructured":"Koutoulidis V, Terpos E, Klapa I, Cheliotis G, Ntanasis-Stathopoulos I, Boultadaki A, et al. Whole-body low-dose CT in multiple myeloma: diagnostic value of appendicular medullary patterns of attenuation. AJR Am J Roentgenol. 2021;216(3):742\u201351.","journal-title":"AJR Am J Roentgenol"},{"key":"7599_CR10","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, D\u00fcrig J, Schroers R, von Metzler I, H\u00e4nel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, M\u00fcller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810-e821."},{"key":"7599_CR11","unstructured":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, H\u00e4nel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, M\u00fcller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 Trial. J Clin Oncol. 2024;9:JCO2402266."},{"issue":"965","key":"7599_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1259\/bjr\/21850180","volume":"81","author":"M Horger","year":"2008","unstructured":"Horger M, Pereira P, Claussen CD, Kanz L, Vonthein R, Denecke B, et al. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol. 2008;81(965):386\u201396.","journal-title":"Br J Radiol"},{"issue":"7","key":"7599_CR13","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1038\/bcj.2015.57","volume":"5","author":"Y Nishida","year":"2015","unstructured":"Nishida Y, Matsue Y, Suehara Y, Fukumoto K, Fujisawa M, Takeuchi M, et al. Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. Blood Cancer J. 2015;5(7):e329.","journal-title":"Blood Cancer J."},{"issue":"1","key":"7599_CR14","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1038\/s41598-017-13255-w","volume":"7","author":"Y Nishida","year":"2017","unstructured":"Nishida Y, Kimura S, Mizobe H, Yamamichi J, Kojima K, Kawaguchi A, et al. Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. Sci Rep. 2017;7(1):12885.","journal-title":"Sci Rep."},{"issue":"2","key":"7599_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bell\u00f2 M, et al. 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30(2):417\u201322.","journal-title":"Leukemia"},{"issue":"3","key":"7599_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPetus (Italian myeloma criteria for PET use). Eur J Nucl Med Mol Imaging. 2016;43(3):414\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7599_CR17","doi-asserted-by":"crossref","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45(5):712-719.","DOI":"10.1007\/s00259-017-3909-8"},{"issue":"12","key":"7599_CR18","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00259-023-06339-5","volume":"50","author":"C Sachpekidis","year":"2023","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Jauch A, et al. Application of an artificial intelligence-based tool in [18F]FDG PET\/CT for the assessment of bone marrow involvement in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023;50(12):3697\u2013708.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7599_CR19","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00259-024-06668-z","volume":"51","author":"C Sachpekidis","year":"2024","unstructured":"Sachpekidis C, Enqvist O, Ul\u00e9n J, Kopp-Schneider A, Pan L, Mai EK, et al. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET\/CT predicts survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2024;51(8):2293\u2013307.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7599_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40658-020-00316-9","volume":"7","author":"E Tr\u00e4g\u00e5rdh","year":"2020","unstructured":"Tr\u00e4g\u00e5rdh E, Borrelli P, Kaboteh R, Gillberg T, Ul\u00e9n J, Enqvist O, et al. RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. EJNMMI Phys. 2020;7(1):51.","journal-title":"EJNMMI Phys."},{"issue":"26","key":"7599_CR21","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol."},{"issue":"10","key":"7599_CR22","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103.","journal-title":"Leukemia"},{"issue":"8","key":"7599_CR23","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1002\/cncr.22572","volume":"109","author":"M Horger","year":"2007","unstructured":"Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer. 2007;109(8):1617\u201326.","journal-title":"Cancer."},{"issue":"9","key":"7599_CR24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","volume":"20","author":"AS Al Saleh","year":"2020","unstructured":"Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, et al. Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2020;20(9):596\u2013601.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7599_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.V75.4.823.823","volume":"75","author":"BG Durie","year":"1990","unstructured":"Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group sStudy. Blood. 1990;75:823\u201330.","journal-title":"Blood"},{"key":"7599_CR26","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","volume":"97","author":"T Facon","year":"2001","unstructured":"Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevi\u00e8ve F, Zandecki M, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566\u201371.","journal-title":"Blood"},{"key":"7599_CR27","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"2018","key":"7599_CR28","first-page":"4198673","volume":"30","author":"S Deng","year":"2018","unstructured":"Deng S, Zhang B, Zhou Y, Xu X, Li J, Sang S, et al. The role of 18F-FDG PET\/CT in multiple myeloma staging according to IMPeTUs: comparison of the durie-salmon plus and other staging systems. Contrast Media Mol Imaging. 2018;30(2018):4198673.","journal-title":"Contrast Media Mol Imaging."},{"issue":"13","key":"7599_CR29","doi-asserted-by":"publisher","first-page":"100598","DOI":"10.1016\/j.ejro.2024.100598","volume":"3","author":"S Xu","year":"2024","unstructured":"Xu S, Jiao S, Guo H, Chen W, Yao S. IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma. Eur J Radiol Open. 2024;3(13):100598.","journal-title":"Eur J Radiol Open."},{"issue":"7","key":"7599_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","volume":"33","author":"L Rasche","year":"2019","unstructured":"Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713\u201322.","journal-title":"Leukemia"},{"issue":"8","key":"7599_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ajh.25507","volume":"94","author":"R Alonso","year":"2019","unstructured":"Alonso R, Cedena MT, G\u00f3mez-Grande A, R\u00edos R, Moraleda JM, Caba\u00f1as V, et al. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol. 2019;94(8):853\u201361.","journal-title":"Am J Hematol"},{"issue":"7","key":"7599_CR32","first-page":"2049","volume":"109","author":"R Szalat","year":"2024","unstructured":"Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024;109(7):2049\u201359.","journal-title":"Haematologica."},{"issue":"Supplement 1","key":"7599_CR33","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1182\/blood-2018-99-115201","volume":"132","author":"S Sauer","year":"2018","unstructured":"Sauer S, Sachpekidis C, Brandelik S, et al. Prospective evaluation of 18-F FDG PET\/CT and biopsies of osteolytic lesions and random bone marrow samples in newly diagnosed multiple myeloma patients. Blood. 2018;132(Supplement 1):3180.","journal-title":"Blood"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07599-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:42:55Z","timestamp":1769834575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07599-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7599"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07599-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants enrolled in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish has been received from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Hartmut Goldschmidt declares the following:Grants and\/or provision of Investigational Medicinal Product: Amgen, Array Biopharma\/Pfizer, BMS\/Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Mundipharma GmbH, Sanofi.Research Support: Amgen, BMS, Celgene, GlycoMimetics Inc., GSK, Heidelberg Pharma, Hoffmann-La Roche, Karyopharm, Janssen, Incyte Corporation, Millenium Pharmaceuticals Inc., Molecular Partners, Merck Sharp and Dohme (MSD), MorphoSys AG, Pfizer, Sanofi, Takeda, Novartis.Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Janssen, Sanofi, Honoraria \/ Nebent\u00e4tigkeiten: Amgen, BMS, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer.Support for attending meetings and\/or travel: Amgen, BMS, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi, Pfizer.Elias K. Mai reports the following:Consulting or advisory role: Bristol Myers Squibb\/Celgene, GlaxoS- mithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda.Honoraria: Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen- Cilag, Sanofi Aventis, Stemline, Takeda.Research funding: Sanofi Aventis.Travel accommodations and expenses: Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi Aventis, Stemline, Takeda.All other authors declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}